In research published today in The Lancet and funded by
Researchers say pioneering emergency eye care trial leads to quicker treatment times
A trial virtual emergency consultation programme for eye patients has
Large placebo-controlled trial confirms safety of proton pump inhibitors (PPIs)
For patients taking proton pump inhibitors (PPIs) to treat gastroesophageal
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., April 15, 2019 (GLOBE NEWSWIRE) — MediciNova,
Trial to answer dilemma of treating childhood epilepsy
One of the largest ever clinical trials in children with
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in
X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P 001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial
CAMBRIDGE, MA – December 1, 2018 – X4 Pharmaceuticals, a
Trial examines how mindfulness meditation may improve mood
In a randomized controlled trial of 134 mildly stressed, middle-aged
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc.
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors
WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 23, 2018– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a